BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 37658563)

  • 1. Biomarkers in neuroendocrine neoplasms.
    Zouli C; Zisimopoulou E; Chrisoulidou A
    Hell J Nucl Med; 2023; 26 Suppl():44-48. PubMed ID: 37658563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical significance of blood chromogranin A measurement in neuroendocrine tumours.
    Seregni E; Ferrari L; Bajetta E; Martinetti A; Bombardieri E
    Ann Oncol; 2001; 12 Suppl 2():S69-72. PubMed ID: 11762355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidemiology, clinical features and diagnosis of gastroenteropancreatic endocrine tumours.
    Tomassetti P; Migliori M; Lalli S; Campana D; Tomassetti V; Corinaldesi R
    Ann Oncol; 2001; 12 Suppl 2():S95-9. PubMed ID: 11762360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic factors for gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): what's better?
    Milione M
    Endocrine; 2018 Jan; 59(1):1-3. PubMed ID: 28417314
    [No Abstract]   [Full Text] [Related]  

  • 5. Chromogranin A in diagnosing and monitoring patients with gastroenteropancreatic neuroendocrine neoplasms: a large series from a single institution.
    Massironi S; Rossi RE; Casazza G; Conte D; Ciafardini C; Galeazzi M; Peracchi M
    Neuroendocrinology; 2014; 100(2-3):240-9. PubMed ID: 25428270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicopathological features and prognosis of gastroenteropancreatic neuroendocrine neoplasms in a Chinese population: a large, retrospective single-centre study.
    Zhang M; Zhao P; Shi X; Zhao A; Zhang L; Zhou L
    BMC Endocr Disord; 2017 Jul; 17(1):39. PubMed ID: 28705205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Neuroendocrine Neoplasms of the Digestive Tract: Diagnosis, Treatment and Nutrition.
    Pobłocki J; Jasińska A; Syrenicz A; Andrysiak-Mamos E; Szczuko M
    Nutrients; 2020 May; 12(5):. PubMed ID: 32429294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Chinese expert consensus on gastroenteropancreatic neuroendocrine neoplasms (2022 edition)].
    Expert Committee on Neuroendocrine Neoplasms, Chinese Society of Clinical Oncology
    Zhonghua Zhong Liu Za Zhi; 2022 Dec; 44(12):1305-1329. PubMed ID: 36575783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biochemistry of neuroendocrine tumours.
    de Herder WW
    Best Pract Res Clin Endocrinol Metab; 2007 Mar; 21(1):33-41. PubMed ID: 17382264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Variability of the Ki-67 proliferation index in gastroenteropancreatic neuroendocrine neoplasms - a single-center retrospective study.
    Shi H; Zhang Q; Han C; Zhen D; Lin R
    BMC Endocr Disord; 2018 Jul; 18(1):51. PubMed ID: 30055596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pathological characteristics and survival analysis of 355 patients with gastroenteropancreatic neuroendocrine neoplasms].
    Li Y; Wang YF; Tan BB; Er LM; Zhao Q; Fan LQ; Zhang ZD; Liu Y
    Zhonghua Zhong Liu Za Zhi; 2020 May; 42(5):426-431. PubMed ID: 32482035
    [No Abstract]   [Full Text] [Related]  

  • 12. Biochemical markers for gastroenteropancreatic neuroendocrine tumours (GEP-NETs).
    Kanakis G; Kaltsas G
    Best Pract Res Clin Gastroenterol; 2012 Dec; 26(6):791-802. PubMed ID: 23582919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The archaic distinction between functioning and nonfunctioning neuroendocrine neoplasms is no longer clinically relevant.
    Modlin IM; Moss SF; Gustafsson BI; Lawrence B; Schimmack S; Kidd M
    Langenbecks Arch Surg; 2011 Dec; 396(8):1145-56. PubMed ID: 21523447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Lanreotide Depot/Autogel on Urinary 5-Hydroxyindoleacetic Acid and Plasma Chromogranin A Biomarkers in Nonfunctional Metastatic Enteropancreatic Neuroendocrine Tumors.
    Pavel ME; Phan AT; Wolin EM; Mirakhur B; Liyanage N; Pitman Lowenthal S; Fisher GA; Vinik AI;
    Oncologist; 2019 Apr; 24(4):463-474. PubMed ID: 30355775
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinicopathological heterogeneity between primary and metastatic sites of gastroenteropancreatic neuroendocrine neoplasm.
    Shi H; Jiang C; Zhang Q; Qi C; Yao H; Lin R
    Diagn Pathol; 2020 Sep; 15(1):108. PubMed ID: 32917216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insulinoma-associated protein 1 expression in primary and metastatic neuroendocrine neoplasms of the gastrointestinal and pancreaticobiliary tracts.
    González I; Lu HC; Sninsky J; Yang C; Bishnupuri K; Dieckgraefe B; Cao D; Chatterjee D
    Histopathology; 2019 Oct; 75(4):568-577. PubMed ID: 31077609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An update on the diagnosis of gastroenteropancreatic neuroendocrine neoplasms.
    Fang JM; Li J; Shi J
    World J Gastroenterol; 2022 Mar; 28(10):1009-1023. PubMed ID: 35431496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Gastroenteropancreatic neuroendocrine tumors : (GEP-NENs)].
    Sebesta C; Feichter A; Selimi F
    Wien Med Wochenschr; 2023 Jun; 173(9-10):221-226. PubMed ID: 36512264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New insights in diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms.
    Yin F; Wu ZH; Lai JP
    World J Gastroenterol; 2022 May; 28(17):1751-1767. PubMed ID: 35633912
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hormone secreting gastro-entero-pancreatic neuroendocrine neoplasias (GEP-NEN): When to consider, how to diagnose?
    Fottner C; Ferrata M; Weber MM
    Rev Endocr Metab Disord; 2017 Dec; 18(4):393-410. PubMed ID: 29256148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.